Zhi Jian Chen

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.

Part of Huatai Securities Co., Ltd., Huatai Futures Co., Ltd. provides investment brokerage and asset management services. The company is based in Guangzhou, China. The Chinese company was founded in 1994. The CEO is Chang Tao Zhao.